Phase I/II Study of Yttrium-90 Labeled Anti-CD25 (a-Tac) Monoclonal Antibody Plus BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma, the "a-Tac BEAM Regimen"
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Basiliximab; Basiliximab Y-90; Carmustine; Cytarabine; Etoposide; Indium-111-basiliximab; Melphalan
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 10 Mar 2021 Biomarkers information updated
- 16 Nov 2012 Planned end date changed from 1 Jan 2020 to 1 Jan 2021 as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.